SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the December 2025 quarter moved down -34.07% to Rs. 584.88 millions as compared to Rs. 887.12 millions during the year ago period.The Net Loss for the quarter ended December 2025 is Rs. -97.78 millions as compared to Net Profit of Rs. 14.02 millions of corresponding quarter ended December 2024Operating profit Margin for the quarter ended December 2025 slipped to -13.58% as compared to 88.99% of corresponding quarter ended December 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 584.88 887.12 -34.07 1653.81 2451.92 -32.55 3182.30 3685.95 -13.66
Other Income 1.11 1.31 -15.27 1.39 2.87 -51.57 4.98 0.98 408.16
PBIDT -13.58 88.99 -115.26 -86.64 259.50 -133.39 363.00 174.92 107.52
Interest 40.53 34.89 16.17 131.25 109.18 20.21 149.33 139.17 7.30
PBDT -54.11 54.10 -200.02 -217.89 150.32 -244.95 213.67 35.75 497.68
Depreciation 43.66 39.28 11.15 132.81 117.69 12.85 163.78 146.32 11.93
PBT -97.77 14.82 -759.72 -350.70 32.63 -1174.78 49.89 -110.57 -145.12
TAX 0.01 0.80 -98.75 -43.19 -35.10 23.05 -19.35 -20.08 -3.64
Deferred Tax 0.00 0.80 0.00 8.00 -20.20 -139.60 -20.18 -22.00 -8.27
PAT -97.78 14.02 -797.43 -307.51 67.73 -554.02 69.24 -90.49 -176.52
Equity 158.28 158.28 0.00 158.28 158.28 0.00 158.28 158.28 0.00
PBIDTM(%) -2.32 10.03 -123.15 -5.24 10.58 -149.50 11.41 4.75 140.37

Mangalam Drugs&Org. Share Price

30.56 -0.62 (-1.99%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×